GNOM vs. GERM
GNOM (Global X Genomics & Biotechnology ETF) and GERM (Amplify Treatments, Testing and Advancements ETF) are both Health & Biotech Equities funds - GNOM tracks the Solactive Genomics Index while GERM tracks the Prime Treatments, Testing and Advancements Index. Both are passively managed. Over the past year, GNOM returned 54.21% vs 0.00% for GERM. GNOM charges 0.50%/yr vs 0.68%/yr for GERM.
Performance
GNOM vs. GERM - Performance Comparison
Loading charts...
Returns By Period
GNOM
- 1D
- 1.99%
- 1M
- 5.82%
- YTD
- 7.81%
- 6M
- 6.65%
- 1Y
- 54.21%
- 3Y*
- -0.94%
- 5Y*
- -10.20%
- 10Y*
- —
GERM
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 0.00%
- 6M
- 0.00%
- 1Y
- 0.00%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
GNOM vs. GERM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 7.81% | 18.65% | -9.08% |
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% |
GNOM vs. GERM - Sectors Allocation Comparison
Sectors
GNOM
GERM
Healthcare
Technology
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Industrials
-
-
Real Estate
-
-
Utilities
-
-
Healthcare
GNOM
GERM
Technology
GNOM
GERM
-
Basic Materials
GNOM
-
GERM
-
Communication Services
GNOM
-
GERM
-
Consumer Cyclical
GNOM
-
GERM
-
Consumer Defensive
GNOM
-
GERM
-
Energy
GNOM
-
GERM
-
Financial Services
GNOM
-
GERM
Industrials
GNOM
-
GERM
-
Real Estate
GNOM
-
GERM
-
Utilities
GNOM
-
GERM
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM vs. GERM — Risk / Return Rank
GNOM
GERM
GNOM vs. GERM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOM | GERM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.33 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 3.00 | — | — |
| Martin ratioReturn relative to average drawdown | 8.62 | — | — |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GNOM | GERM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.06 | — | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.31 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.09 | — | — |
Drawdowns
GNOM vs. GERM - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for GNOM and GERM.
Loading charts...
Drawdown Indicators
| GNOM | GERM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | 0.00% | -75.00% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | 0.00% | -18.17% |
Max Drawdown (3Y)Largest decline over 3 years | -46.47% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | — | — |
Current DrawdownCurrent decline from peak | -55.45% | 0.00% | -55.45% |
Average DrawdownAverage peak-to-trough decline | -40.55% | 0.00% | -40.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.30% | 0.00% | +6.30% |
Volatility
GNOM vs. GERM - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.47% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM | GERM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.47% | 0.00% | +8.47% |
Volatility (6M)Calculated over the trailing 6-month period | 19.44% | 0.00% | +19.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.50% | 0.00% | +26.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.57% | 0.00% | +33.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.17% | 0.00% | +34.17% |
GNOM vs. GERM - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is lower than GERM's 0.68% expense ratio.
Dividends
GNOM vs. GERM - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.27%, while GERM has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GNOM Global X Genomics & Biotechnology ETF | 1.27% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% |
Frequently Asked Questions
GNOM has higher volatility (8.47%) compared to GERM (0.00%). In terms of maximum drawdown, GNOM dropped -75.00% vs GERM's 0.00%.
On 1-year performance, GNOM leads with 54.21% vs 0.00% for GERM. On fees, GNOM is cheaper at 0.50% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 1-year period, GNOM has performed better with a 54.21% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
GNOM is cheaper with a 0.50% expense ratio, compared with 0.68% for GERM.
GNOM has the higher dividend yield at 1.27%, compared with 0.00% for GERM.
GNOM tracks Solactive Genomics Index, while GERM tracks Prime Treatments, Testing and Advancements Index. They also come from different issuers: Global X and Amplify. Their fees differ too: 0.50% for GNOM and 0.68% for GERM.
Find the right allocation for GNOM and GERM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer